Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration

Muhammad Raza Cheema, Joanna DaCosta, James Talks Department of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UKCorrespondence: Muhammad Raza CheemaDepartment of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne NE1 4LP,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cheema MR, DaCosta J, Talks J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	neovascular age-related macular degeneration visual acuity real-world anti-vascular endothelial growth factor injections. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0a44f07251574fb99aa94a34bb07b03a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a44f07251574fb99aa94a34bb07b03a
record_format	dspace
spelling	oai:doaj.org-article:0a44f07251574fb99aa94a34bb07b03a2021-12-02T13:51:18ZTen-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration1177-5483https://doaj.org/article/0a44f07251574fb99aa94a34bb07b03a2021-01-01T00:00:00Zhttps://www.dovepress.com/ten-year-real-world-outcomes-of-anti-vascular-endothelial-growth-facto-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Muhammad Raza Cheema, Joanna DaCosta, James Talks Department of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UKCorrespondence: Muhammad Raza CheemaDepartment of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne NE1 4LP, UKTel +44-191-233-6161Email drmrcheema@hotmail.comBackground: Neovascular age-related macular degeneration (nAMD) has been treated with anti-vascular endothelial growth factor (anti-VEGF) therapy since 2006 with initial efficacy evidence of 2 years. In many, long-term therapy is required, and evidence for benefit is required from real-world data collection.Methods: Retrospective review of electronic medical records of a consecutive series of patients treated with anti-VEGF therapy for nAMD over a 10-year period. Age, lens status and loss to follow-up was recorded. Primary outcome was change in VA at 10 years; secondary outcomes included proportion of eyes losing < 15 letters at 3, 5, 7 and 10 years, number of injections and anatomic outcome.Results: Of 196 patients (197 eyes), 90 patients had 10 years of follow-up data. Visual acuity (VA) declined by − 11.2 letters (p=0.001), but 63.3% of eyes lost ≤ 15 letters. The proportion of eyes maintaining ≥ 70 letters was 17.7%, and the mean number of injections (±SD) was 47 ± 16. Retinal fluid was still present in 72.2% of eyes at 10 years. Forty-six percent of patients continued to receive anti-VEGF injections 10 years after treatment was commenced.Conclusion: Anti-VEGF treatment for nAMD over a ten-year period showed 63.3% of eyes lost ≤ 15 letters. Eyes with better baseline vision were more likely to continue receiving anti-VEGF treatment, but the frequency of injection treatment decreased.Keywords: neovascular age-related macular degeneration, visual acuity, real-world, anti-vascular endothelial growth factor injectionsCheema MRDaCosta JTalks JDove Medical Pressarticleneovascular age-related macular degenerationvisual acuityreal-worldanti-vascular endothelial growth factor injections.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 279-287 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	neovascular age-related macular degeneration visual acuity real-world anti-vascular endothelial growth factor injections. Ophthalmology RE1-994
spellingShingle	neovascular age-related macular degeneration visual acuity real-world anti-vascular endothelial growth factor injections. Ophthalmology RE1-994 Cheema MR DaCosta J Talks J Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
description	Muhammad Raza Cheema, Joanna DaCosta, James Talks Department of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UKCorrespondence: Muhammad Raza CheemaDepartment of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne NE1 4LP, UKTel +44-191-233-6161Email drmrcheema@hotmail.comBackground: Neovascular age-related macular degeneration (nAMD) has been treated with anti-vascular endothelial growth factor (anti-VEGF) therapy since 2006 with initial efficacy evidence of 2 years. In many, long-term therapy is required, and evidence for benefit is required from real-world data collection.Methods: Retrospective review of electronic medical records of a consecutive series of patients treated with anti-VEGF therapy for nAMD over a 10-year period. Age, lens status and loss to follow-up was recorded. Primary outcome was change in VA at 10 years; secondary outcomes included proportion of eyes losing < 15 letters at 3, 5, 7 and 10 years, number of injections and anatomic outcome.Results: Of 196 patients (197 eyes), 90 patients had 10 years of follow-up data. Visual acuity (VA) declined by − 11.2 letters (p=0.001), but 63.3% of eyes lost ≤ 15 letters. The proportion of eyes maintaining ≥ 70 letters was 17.7%, and the mean number of injections (±SD) was 47 ± 16. Retinal fluid was still present in 72.2% of eyes at 10 years. Forty-six percent of patients continued to receive anti-VEGF injections 10 years after treatment was commenced.Conclusion: Anti-VEGF treatment for nAMD over a ten-year period showed 63.3% of eyes lost ≤ 15 letters. Eyes with better baseline vision were more likely to continue receiving anti-VEGF treatment, but the frequency of injection treatment decreased.Keywords: neovascular age-related macular degeneration, visual acuity, real-world, anti-vascular endothelial growth factor injections
format	article
author	Cheema MR DaCosta J Talks J
author_facet	Cheema MR DaCosta J Talks J
author_sort	Cheema MR
title	Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
title_short	Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
title_full	Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
title_fullStr	Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
title_full_unstemmed	Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
title_sort	ten-year real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/0a44f07251574fb99aa94a34bb07b03a
work_keys_str_mv	AT cheemamr tenyearrealworldoutcomesofantivascularendothelialgrowthfactortherapyinneovascularagerelatedmaculardegeneration AT dacostaj tenyearrealworldoutcomesofantivascularendothelialgrowthfactortherapyinneovascularagerelatedmaculardegeneration AT talksj tenyearrealworldoutcomesofantivascularendothelialgrowthfactortherapyinneovascularagerelatedmaculardegeneration
_version_	1718392360813985792

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration

Ejemplares similares